Premium
Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients
Author(s) -
Science Michelle,
Robinson Paula D.,
MacDonald Tamara,
Rassekh Shahrad Rod,
Dupuis L. Lee,
Sung Lillian
Publication year - 2014
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24847
Subject(s) - medicine , guideline , hematopoietic stem cell transplantation , neutropenia , myelodysplastic syndromes , context (archaeology) , intensive care medicine , antifungal , myeloid leukemia , cancer , oncology , transplantation , chemotherapy , pathology , dermatology , bone marrow , paleontology , biology
Abstract This guideline provides clinicians with evidence‐based recommendations on the use of antifungal prophylaxis in children with cancer and undergoing hematopoietic stem cell transplantation (HSCT). Recommendations are divided into: (1) allogeneic HSCT (2) autologous HSCT (3) acute myeloid leukemia or myelodysplastic syndrome and (4) patients with malignancy and neutropenia for >7 days. A systematic review was conducted and evidence summaries compiled. The quality of evidence and strength of each recommendation was determined using GRADE. Implementation of these recommendations will require adaptation to local context. The contribution of this guideline in the prevention of invasive fungal infections requires prospective evaluation. Pediatr Blood Cancer 2014;61:393–400. © 2013 Wiley Periodicals, Inc.